Avalo Therapeutics, Inc. - Common Stock, $0.001 par value (AVTX)

CUSIP: 05338F306

Q3 2025 13F Holders as of 30 Sep 2025

Security type / class
Equity / Common Stock, $0.001 par value
Total 13F shares
15,317,685
Total 13F value
$194,685,792
Holder snapshot 6 visible 7 signals
Share change
+7,474,645
Put/Call ratio
46%
SEC-reported price per share
$12.71
Number of holders
65
Value change
+$95,069,684
Number of buys
47
Open additional details 1 more signal available
Number of sells
10
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
57,788,980

Security key

05338F306

Report period

Q3 2025

Institutions

65

Top holders

10

AVTX full security history Ownership snapshot Full 13F holder table Newer quarter: Q4 2025 Previous quarter: Q2 2025 Avalo Therapeutics, Inc. SEC filings Avalo Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of AVTX - Avalo Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Nantahala Capital Managem...
Disclosed value leader
Nantahala Capital Managem...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G 13F Lead comparable stake: 9.4% 13D/G row: Nantahala Capital Management, LLC Showing 1-6 of 15 holder rows.

Quick read

Nantahala Capital Management, LLC leads the comparable SEC ownership view at 9.4%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Nantahala Capital Management, LLC's linked filing trail.
Comparable ownership Top 5
Nantahala Capital Management, LLC 9.4%
Patrick J. Crutcher 4.2%
Ikarian Capital, LLC 3.8%
BVF INC/IL 1.8%
ORBIMED ADVISORS LLC 1.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Nantahala Capital Management, LLC
13D/G 13F
Company
13D/G 13F
9.4%
$15,696,850
1,235,000 shares
 +$4,257,850 30 Sep 2025
Patrick J. Crutcher
13D/G
13D/G
4.2%
$3,593,514
549,467 shares
 $0 06 Aug 2025
Ikarian Capital, LLC
13D/G 13F
Company
13D/G 13F
3.8%
$9,049,101
711,967 shares
 -$6,100,673 30 Sep 2025
BVF INC/IL
13F
Company
13F
1.8%
$5,129,965
1,028,049 shares
 — 30 Jun 2025
ORBIMED ADVISORS LLC
13F
Company
13F
1.7%
$4,825,330
967,000 shares
 — 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
1.6%
$4,655,535
932,973 shares
 — 30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
65
Shares
15,317,685
Rows available
65
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
35
Q3 2025 holders
65
Holder diff
30
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .